Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































How States Can Join Civica Rx and Blue Cross Blue Shield’s Partnership for an Affordable, Sustainable Supply of Generics
/in Policy Blogs, Featured News Home Administrative Actions, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckMore than 50 major health systems, including hospitals in every state, have joined forces to create Civica Rx, a nonprofit drug manufacturer that produces affordable, sustainable supplies of certain generic medications – a mission made more critical than ever by generic shortages related to the COVID-19 pandemic.
States with Transparency Laws Monitor Prices of Potential COVID-19 Drug Treatments
/in COVID-19 State Action Center Blogs, Featured News Home Administrative Actions, COVID-19, Legal Resources, Prescription Drug Pricing, State Rx Legislative Action COVID-19 /by Johanna Butler and Jennifer ReckAbsent sufficient evidence from clinical trials that proves a variety of drugs are effective against COVID-19, many states are providing guidance to limit their use and have begun monitoring them for price increases and shortages. Building on experience from states’ drug price transparency laws, policymakers now have tools to track these drug costs and identify […]
States Act to Protect Consumers against Unproven COVID-19 Drugs and Safeguard Supplies as FDA Approves Limited Use
/in COVID-19 State Action Center Blogs, Featured News Home Administrative Actions, Consumer Affordability, COVID-19, Health System Costs, Prescription Drug Pricing /by Trish Riley and Sarah LanfordAt least 11 states have acted to limit the dispensing of chloroquine and hydroxychloroquine – prescription drugs that have been cited as providing protection against coronavirus (COVID-19) without adequate clinical evidence to support that claim. To protect consumers with or at risk of COVID-19 and to prevent stockpiling of these drugs, which treat malaria, rheumatoid […]
Webinar: BCBS Plans and Civica Rx Partner to Produce Lower-Cost Generic Drugs – Opportunities for States
/in Policy Webinars Administrative Actions, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffNASHP Responds to Proposed, Landmark Federal Drug Importation Rule: Changes Needed
/in Policy Colorado, Florida, Maine, Vermont Blogs, Featured News Home Administrative Actions, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Trish RileyQ&A: How Maryland’s First-in-the-Nation Rx Affordability Board Is Faring
/in Policy Maryland Blogs, Featured News Home Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Jennifer ReckMaryland’s first-in-the-nation Prescription Drug Affordability Board (PDAB), enacted last year, has the authority to set upper payment limits for certain high-cost drugs purchased by state and local government. The board is also tasked with proposing a plan to extend upper payment limits to all purchasers in the state. This Q&A provides an update on Maryland’s […]
Proposed Rule Could Save Consumers Millions by Changing the Insurer-PBM Relationship, Comments Due March 2
/in Policy Blogs, Featured News Home Administrative Actions, Health Coverage and Access, Prescription Drug Pricing, State Insurance Marketplaces, State Rx Legislative Action /by Sarah Lanford and Maureen Hensley-QuinnGovernors Tackle Health Care Costs, Coverage, and Quality in their State of the State Addresses
/in Policy Blogs, Featured News Home Behavioral/Mental Health and SUD, Chronic and Complex Populations, Chronic Disease Prevention and Management, Cost, Payment, and Delivery Reform, Health Coverage and Access, Health Equity, Health System Costs, Healthy Child Development, Maternal, Child, and Adolescent Health, Medicaid Expansion, Population Health, Prescription Drug Pricing, Safety Net Providers and Rural Health, Social Determinants of Health, State Insurance Marketplaces, State Rx Legislative Action, Work Requirements /by Sarah Lanford and Anita CardwellIn their 2020 state of the state speeches, governors identified new health policy initiatives on a wide range of issues. As of mid-February, 42 governors had delivered speeches or outlined key budget priorities, and all addressed health issues – most commonly strategies to tackle health care costs and behavioral health issues. Below are highlights of the key health themes […]
How Governors Addressed Health Care in their 2020 State of the State Addresses
/in Policy Charts Behavioral/Mental Health and SUD, Chronic and Complex Populations, Chronic Disease Prevention and Management, Cost, Payment, and Delivery Reform, Health Coverage and Access, Health Equity, Health System Costs, Healthy Child Development, Infant Mortality, Integrated for Pregnant/Parenting Women, Maternal Health and Mortality, Maternal, Child, and Adolescent Health, Medicaid Expansion, Medicaid Managed Care, Medicaid Managed Care, Medicaid Managed Care, Population Health, Prescription Drug Pricing, Social Determinants of Health, State Insurance Marketplaces, State Rx Legislative Action, Work Requirements /by Sarah Lanford and Anita CardwellQ&A: The Facts about Canadian Drug Shortages
/in Policy Blogs, Featured News Home Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by Johanna Butler